THEO-260 not checked

Theolytics Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Ovarian Cancer (2 trials)
Main trialPhase 1/2
“A research study evaluating a new oncolytic virus, THEO-260, in patients with advanced ovarian cancer. The trial will investigate different doses of THEO-260 administered intravenously to identify a dose that is safe, well tolerated, and exhibits preliminary evidence of anti tumour activity.”In the company’s words, NCT06618235 on ClinicalTrials.gov

Other drugs for Ovarian Cancer

All 265 drugs for Ovarian Cancer

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Jun 2028 Trial of THEO-260 in Ovarian Cancer Patients
Phase 1Recruiting Sep 2027 Trial of THEO-260 (Administered Via Intraperitoneal Route) in Ovarian Cancer Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow THEO-260

Following is part of Solo: you see every change to THEO-260 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in